Vascarta's STO-1 Achieves 67% Survival Rate in Preclinical Glioblastoma Study
Key Insights
Vascarta and CUNY (search) published preclinical data showing STO-1 (search), a curcumin-paclitaxel hybrid molecule, achieved 67% long-term survival in glioblastoma (search)-bearing mice with several animals experiencing complete tumor clearance.
The first-in-class drug candidate selectively targets tumor-associated immune cells (search) while avoiding harmful autoimmune reactions commonly seen with other immunotherapies.
STO-1 (search) works by reprogramming deactivated tumor-associated immune cells (search) to attack glioblastoma (search) tumors while preserving healthy immune function.
Vascarta Inc. (search) and the City University of New York (CUNY (search)) have published preclinical data demonstrating that their first-in-class drug candidate STO-1 (search) achieved a 67% long-term survival rate in mice with glioblastoma (search), with several animals experiencing complete tumor clearance. The study represents a significant advance in treating the most aggressive form of brain cancer while avoiding the dangerous autoimmune reactions associated with current immunotherapies.
Novel Hybrid Molecule Design
STO-1 (search) is a proprietary hybrid molecule that combines curcumin with paclitaxel through a specialized linker that breaks when the drug enters a cell. This unique design allows the therapy to selectively eliminate glioblastoma (search) cells while preserving healthy tissue function.
The therapy works by reprogramming deactivated tumor-associated immune cells (search) to attack the tumor, while leaving healthy immune function intact. This mechanism minimizes the prospect of undesirable side effects often seen with immunotherapies, addressing a major limitation of current treatment approaches.
Selective Targeting Without Autoimmune Risk
Dr. Probal Banerjee, the senior author and Professor of Biochemistry, Biology, Neuroscience, and Chemistry at the College of Staten Island, CUNY (search), emphasized the safety profile of the approach. "Unlike other immune therapies, which can trigger dangerous autoimmune reactions, STO-1 (search) targets only the tumor-associated cells. This study demonstrates a promising new approach to treating glioblastoma (search) safely."
The selective targeting mechanism represents a significant advancement over existing immunotherapies, which often struggle with balancing efficacy against autoimmune complications.
Addressing Critical Unmet Need
Glioblastoma (search) is the most common and aggressive form of malignant brain tumor in adults, affecting more than 13,000 Americans each year. Current treatments include surgery, radiation, chemotherapy, and experimental immunotherapies, but outcomes remain poor.
Dr. Richard Prince, Chairman, Chief Executive and President of Vascarta, stated: "These results highlight the potential of STO-1 (search) to offer a safe and effective option for patients with glioblastoma (search) without the side effects."
Company Pipeline Context
Vascarta is a healthspan-focused, clinical-stage biopharmaceutical company advancing safe, patient-friendly therapies for pain, inflammation, and cancer. The company's proprietary drug delivery platform supports a growing pipeline of therapies targeting inflammatory diseases and cancer.
The company's lead candidate, Vasceptor® (VAS-101), is a topically applied transdermal formulation utilizing curcumin as its active pharmaceutical ingredient. VAS-101 is advancing following a positive phase I clinical trial in osteoarthritis and is being studied in sickle cell disease by the NIH, as well as preclinically in cancer applications.